Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Personalized NK Cell Therapy in CBT
      Description

      This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or multiple myeloma. This clinical trial will test cord blood (CB) selection for human leukocyte antigen (HLA)-C1/x recipients based on HLA-killer-cell immunoglobulin-like receptor (KIR) typing, and adoptive therapy with CB-derived NK cells for HLA-C2/C2 patients. Natural killer cells may kill tumor cells that remain in the body after chemotherapy treatment and lessen the risk of graft versus host disease after cord blood transplant.

      Conditions
      Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia With Myelodysplasia-Related ChangesAcute Myeloid Leukemia With Variant MLL TranslocationsB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chemotherapy-Related LeukemiaChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsISS Stage II Plasma Cell MyelomaISS Stage III Plasma Cell MyelomaMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess BlastsMyelodysplastic Syndrome With Gene MutationMyelodysplastic/Myeloproliferative NeoplasmPreviously Treated Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Adult Acute Lymphoblastic LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Myelodysplastic Syndrome
      Talk to us